Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer

References

• DeVita VTJr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th edn. Philadelphia: Lippincott Williams; 2001; p. 2655–70.
   Google Scholar
• Markesbery WR, Brooks WH, Gupta GD, Young AB. Treatment for patients with cerebral metastases. Arch Neurol. 1978;35:754–6.
   PubMed Web of Science ®Google Scholar
• Egawa S, Tukiyama I, Akine Y, Kajiura Y, Yanagawa S, Watai K, et al. Radiotherapy of brain metastases. Int J Radiat Oncol Biol Phys. 1986;12:1621–5.
   PubMed Web of Science ®Google Scholar
• Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. AJR Am J Roentgenol. 1971;111:334–6.
   Web of Science ®Google Scholar
• Kim LS, Huang S, Lu W, Lev DC, Price JE. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis. 2004;21:107–18.
   PubMed Web of Science ®Google Scholar
• Bai H, He WZ, Han BH. Relationship of the prognosis of lung cancer with brain metastases and the expressions of p53, nm23 and VEGF. China Oncol. 2007;17:774–8.
   Google Scholar
• JuanYin J, Tracy K, Zhang L, Munasinghe J, Shapiro E, Koretsky A, et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis. 2009;26:403–14.
   PubMed Web of Science ®Google Scholar
• Jubb AM, Cesario A, Ferguson M, Congedo MT, Gatter KC, Lococo F, et al. Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer. 2011;104:1877–81.
   PubMed Web of Science ®Google Scholar
• Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci USA. 2012;109:E3119–27.
   PubMed Web of Science ®Google Scholar
• Wuthrick EJ, Kamrava M, Curran WJ Jr, Werner-Wasik M, Camphausen KA, Hyslop T, et al. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer. 2011;117:5548–59.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Govindan R. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology. Clin Lung Cancer. 2008;9(Suppl 2):S57–S61.
   PubMed Web of Science ®Google Scholar
• Ilie M, Mazure NM, Hofman V, Ammadi RE, Ortholan C, Bonnetaud C, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer. 2012;102:627–35.
   Google Scholar
• Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18:4406–14.
   PubMed Web of Science ®Google Scholar
• Hemmerlein B, Kugler A, Ozisik R, Ringert RH, Radzun HJ, Thelen P. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch. 2001;439:645–52.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;31:359–64.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29:2215–22.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–9.
   PubMed Web of Science ®Google Scholar
• Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al. A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013;31(14):1719–25.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12:713–8.
   PubMed Web of Science ®Google Scholar
• Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757–63.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, et al. Safety of bevacizumab in patients with nonsmall-cell lung cancer and brain metastases. J Clin Oncol. 2009;27:5255–61.
   PubMed Web of Science ®Google Scholar
• Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16:269–78.
   PubMed Web of Science ®Google Scholar
• De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, et al. Efficacy and safety of bevacizumab in active brain metastases from nonsmall cell lung cancer. J Neurooncol. 2010;100:443–7.
   PubMed Web of Science ®Google Scholar
• Furuse M, Kawabata S, Kuroiwa T, Miyatake S. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol. 2011;102:471–5.
   PubMed Web of Science ®Google Scholar
• Jain PK. Normalizing tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
   PubMed Web of Science ®Google Scholar
• Mazzone M, Dettori D, Letite de Oliveira R, Loges S, Schmidt T, Jonckx B, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009;136:839–51.
   PubMed Web of Science ®Google Scholar
• Van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1 alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43:1392–8.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer. 2005;49:325–35.
   PubMed Web of Science ®Google Scholar
• Swinson DE, Cox G, O'Byrne KJ. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. British Journal of Cancer. 2004;91:1301–07.
   Google Scholar